Drugs › Tricyclic antidepressant
Generic name
Doxepin hcl: adverse event reports filed with FDA
1,107 reports list it as a suspect or interacting product, 2004–2024. Class: Tricyclic antidepressant.
- 1,107
- reports as suspect product
- 0% of all reports · about 49 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 81%
- marked serious by the reporter
- 88.7% across the class
- 50.9%
- record death among outcomes, as reported
- 563 reports · not verified by FDA
1,107 adverse event reports received by FDA list doxepin hcl, a generic name as a suspect or interacting product, from January 2004 to February 2024. A further 2,366 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 49 reports a year and 0% of the 20,646,523 reports in the database, and 6.1% of the reports for the tricyclic antidepressant class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are completed suicide (26.1%), cardiac arrest (11.4%) and respiratory arrest (10.1%). A report can list several reactions, so shares add to more than 100%; 289 different terms appear across these reports. Completed suicide is recorded in 26.1% of these reports, a larger share than in the median tricyclic antidepressant drug (17.4%).
81% of the reports are marked serious by the reporter (88.7% across the class); 50.9% record death among the outcomes and 23.1% record hospitalisation, as reported. 41.8% of the reports came from physicians, and the largest patient age group is 45 to 64 (35.2%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Doxepin hcl reports recording the termmedian drug in tricyclic antidepressant
- Completed suicidedeath by suicide26.1%289
- Cardiac arrestthe heart stopped11.4%126
- Respiratory arrestbreathing stopped10.1%112
- Drug hypersensitivityan allergic-type reaction to a medicine9.8%109
- Drug toxicity6.7%74
- Drug abusemisuse of a medicine6%66
- Suicide attempta suicide attempt5.3%59
- Drug interactionan interaction between medicines4.6%51
- Overdosea dose above the recommended amount4.6%51
- Somnolencedrowsiness4.6%51
- Drug ineffectivethe medicine did not work as expected4.5%50
- Toxicity to various agentspoisoning or toxic effect of one or more substances4.4%49
- Deaththe patient died; cause not stated by this term4.3%48
- Multiple drug overdose4%44
- Cardio-respiratory arrestthe heart and breathing stopped3.7%41
- Coma3.4%38
- Multiple drug overdose intentional2.6%29
- Loss of consciousnesspassing out2.5%28
- Tachycardiafast heart rate2.3%25
- Convulsion2.2%24
- Intentional overdosea deliberate overdose2.1%23
- Depressionlow mood2%22
- Tremorshaking2%22
- Dizzinesslight-headedness or unsteadiness1.9%21
- Poisoning1.9%21
- Falla fall1.8%20
- Fatiguetiredness1.8%20
- Hypotensionlow blood pressure1.5%17
- Electrocardiogram QT prolongeda QT prolongation on the ECG1.4%16
- Insomniadifficulty sleeping1.4%15
Top 30 of 289 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 11 drugs in the tricyclic antidepressant class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 18,174 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 71.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Depression | 59 | 5.3% |
| Ill-defined disorder | 46 | 4.2% |
| Sleep disorder | 22 | 2% |
| Insomnia | 13 | 1.2% |
| Anxiety | 6 | 0.5% |
| Suicide attempt | 6 | 0.5% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,107 reports.
In context
| Measure | Doxepin hcl | Tricyclic antidepressant | All reports |
|---|---|---|---|
| Reports as suspect product | 1,107 | 18,174 | 20,646,523 |
| Share of that pool | — | 6.1% | 0% |
| Reports, latest 12 months | 0 | — | 1,332,454 |
| Marked serious | 81% | 88.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 509 | 295 | 91 |
| Hospitalisation recorded, per 1,000 reports | 231 | 351 | 213 |
| Consumer-filed share | 11.7% | 19% | 45.8% |
| Top term, share of reports | Completed suicide 26.1% | median 17.4% | 0.4% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the tricyclic antidepressant class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Amitriptyline hydrochloride | generic | 4,504 | 341 | 90% |
| Doxepin | generic | 3,134 | 193 | 88.7% |
| Amitriptyline hcl | generic | 2,553 | 0 | 91.4% |
| Anafranil | brand | 1,868 | 56 | 96.9% |
| Nortriptyline hydrochloride | generic | 1,702 | 225 | 84.4% |
| Doxepin hydrochloride | generic | 860 | 43 | 78% |
| Pamelor | brand | 678 | 23 | 73.7% |
| Clomipramine hydrochloride | generic | 598 | 73 | 92.1% |
| Trimipramine | generic | 589 | 41 | 98.6% |
| Nortriptyline hcl | generic | 581 | 0 | 86.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Doxepin hcl reports
How many adverse event reports has FDA received for Doxepin hcl?
1,107 reports list Doxepin hcl as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 2,366 list it only as a concomitant medication.
What reactions are recorded in Doxepin hcl reports?
completed suicide (26.1%), cardiac arrest (11.4%), respiratory arrest (10.1%), drug hypersensitivity (9.8%) and drug toxicity (6.7%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Doxepin hcl was responsible.
How serious are the reports?
81% are marked serious by the reporter. Among the outcomes recorded, 50.9% of reports include death and 23.1% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (41.8%), other health professional (24.7%) and pharmacist (13%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Doxepin hcl rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Doxepin hcl was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Doxepin hcl?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Doxepin hcl as a suspect or interacting product; reports listing it only as a concomitant medication (2,366) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.